MedPath

An Open-Label, Single Dose Study to Investigate Striatal Dopamine D2 Receptor Binding of JNJ-37822681 Using [11C]Raclopride Positron Emission Tomography in Healthy Male Subjects

Conditions
schizophrenia
10039628
Registration Number
NL-OMON30989
Lead Sponsor
Johnson & Johnson Pharmaceutical
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
8
Inclusion Criteria

healthy male subjects between 18 - 55 years of age
BMI between 18 and 30 kg/m²

Exclusion Criteria

History of, or currently active, significant illness or medical disorder
Yearly cumulative dose due to exposure to radiation above 10 mSv
Any significant MR abnormalities as determined by a neuroradiologist
Metal implants
Claustrophobia
History of epilepsy or fits or unexplained black-outs
Significant history of or current psychiatric or neurological disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath